The serum concentrations of leptin and MCP-1 independently predict low back pain duration
Authors:
- Giuseppe LippiGLGiuseppe Lippi
- Concetta DagostinoCDConcetta Dagostino
- Ruggero BuonocoreRBRuggero Buonocore
- Rosalia AloeRARosalia Aloe
- Chiara BonaguriCBChiara Bonaguri
- Guido FanelliGFGuido Fanelli
- Massimo AllegriMAMassimo Allegri
- 1 January 2017
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 55 (9) , 1368-1374
Abstract
Background: Low back pain (LBP) is a very frequent condition, affecting most people at some point throughout their life. This cross-sectional study was aimed to investigate a selected panel of cytokines and inflammatory biomarkers in patients with or without LBP.Methods: The study population consisted of 104 patients diagnosed with LBP (52 non-persistent and 52 persistent) and 52 healthy subjects with no LBP. Blood samples were collected for assessment of adiponectin, leptin, monocyte chemoattractant protein-1 (MCP-1) and C reactive protein (CRP). The duration of LBP was categorized as “no pain”, “non-persistent LBP” and “persistent LBP”.Results: Higher values of CRP and lower concentrations of both leptin and MCP-1 were found in LBP patients compared to controls, whereas adiponectin did not differ among groups. MCP-1 was also lower in patients with non-persistent than in those with persistent LBP. Age, leptin (relative risk, 11.8; 95% CI, 3.9–35.8) and MCP-1 (relative risk, 2.7; 95% CI, 1.7–4.4) were independently associated with presence and duration of LBP. The combination of age, leptin and MCP-1 predicted 61% of the risk of LBP duration. The area under the curve of MCP-1 for distinguishing persistent from non-persistent LBP was 0.65 (95% CI, 0.54–0.76).Conclusions: Then results of our study suggest that leptin and MCP-1 may be promising biomarkers for diagnosis of acute LBP and its risk to become chronic.Keywords
This publication has 17 references indexed in Scilit:
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Involvement of spinal monocyte chemoattractant protein-1 (MCP-1) in cancer-induced bone pain in ratsNeuroscience Letters, 2012
- Serum Monocyte Chemotactic Protein-1 Concentrations Distinguish Patients With Ankylosing Spondylitis From Patients With Mechanical Low Back PainJournal of Spinal Disorders & Techniques, 2011
- The Epidemiology of low back painBest Practice & Research Clinical Rheumatology, 2010
- Monocyte Chemoattractant Protein-1 (MCP-1): An OverviewJournal of Interferon & Cytokine Research, 2009
- Spinal leptin contributes to the pathogenesis of neuropathic pain in rodentsJournal of Clinical Investigation, 2009
- The Association between Obesity and the Prevalence of Low Back Pain in Young Adults: The Cardiovascular Risk in Young Finns StudyAmerican Journal of Epidemiology, 2008
- A supermarket approach to the evidence-informed management of chronic low back painThe Spine Journal, 2008
- A New “Kine” of Pain: MCP-1 and Sensory Neuron Excitability. Focus on “MCP-1 Enhances Excitability of Nociceptive Neurons in Chronically Compressed Dorsal Root Ganglia”Journal of Neurophysiology, 2006
- Diagnosis and treatment of low back painBMJ, 2006